Eli Lilly has announced that its humanised monoclonal antibody, Taltz (ixekizumab), yielded good results in a Phase III trial.
The treatment met the primary and all major secondary endpoints in COAST-X, a Phase III study evaluating the safety and efficacy in patients who have non-radiographic axial spondyloarthritis (nr-AxSpA) and are biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve. These results provide clinical evidence to support a potential role for Taltz in the treatment of nr-axSpA patients.
Taltz met the primary endpoint at both week 16 and week 52, demonstrating a statistically significant improvement in the signs and symptoms of nr-axSpA, as measured by the proportion of patients who achieved Assessment of
"Non-radiographic axSpA is a challenging diagnosis that is not only missed in clinics, but also has limited treatment options for physicians to offer patients," said
The American drug-maker announced the findings, making way for a regulatory submission later this year.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting predominantly the sacroiliac joints and the axial skeleton and is estimated to affect 4.5 million adults worldwide.
Taltz is also approved to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.